Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418754 · ClinicalTrials.gov registry record · Phase 2
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 505
- Enrollment target
NCT02418754: Clinical Trial Phase 2 study, sponsored by Regeneron Pharmaceuticals.
NCT02418754 is a Phase 2 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 505 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02418754, a Phase 2 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 505 participants
- Enrollment target
Study Summary
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy. The secondary objectives of the study were the following: * To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12) * To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI. * To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD
Primary Outcome
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means t
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
- DRUG REGN2176-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2017-04-03 |
| Phase | Phase 2 |
Why NCT02418754 stopped before completion
NCT02418754 is an interventional study that assigns participants to a tested intervention. The registered 505 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher).
The record links to 0 conditions, and to 2 interventions - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT02418754 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02418754 about?
NCT02418754 is a clinical study titled "Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)". The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monot...
What is the current status of trial NCT02418754?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 505 participants. The study started on 2015-05-05. Estimated completion is 2017-04-03.
What interventions are being tested in trial NCT02418754?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG), REGN2176-3 (DRUG).
Who is sponsoring clinical trial NCT02418754?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02418754's enrollment target sits among peer trials
505 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI